BCAB Form 4: Eric Sievers Net-Settlement Withholds 2,729 Shares at $0.4555
Rhea-AI Filing Summary
Eric Sievers, Chief Medical Officer of BioAtla, Inc. (BCAB), reported a withholding transaction tied to vested restricted stock units. On 08/31/2025, 2,729 shares were withheld at an effective price of $0.4555 to satisfy income tax and withholding obligations related to prior RSU vesting. After the withholding, the filing shows 364,574 shares beneficially owned by Sievers. The Form 4 was signed by an attorney-in-fact on 09/02/2025. The filing explicitly states this was a net settlement withholding, not an open-market sale.
Positive
- Clear disclosure of the withholding transaction and its purpose (tax and remittance on vested RSUs).
- Compliance with Section 16 reporting shown by timely Form 4 submission and explanatory note.
Negative
- None.
Insights
TL;DR: Routine insider withholding for taxes on vested RSUs; no sale proceeds and limited market impact.
This Form 4 documents a tax-withholding net settlement of previously granted restricted stock units. The withheld amount, 2,729 shares at $0.4555, reduces the reporting person’s post-transaction share count to 364,574. Because shares were withheld rather than sold on the open market, there is no direct change in share supply from a sale event. The disclosure complies with Section 16 reporting requirements and provides transparency on insider equity changes.
TL;DR: Standard compliance disclosure reflecting executive tax withholding on vested equity; governance signals are routine.
The filing indicates appropriate reporting of equity compensation settlement mechanics. Net settlement to cover tax obligations is a common mechanism for RSUs and the form clarifies the nature of the transaction. The signature by an attorney-in-fact is noted, and the explanation field clearly states the transaction was not a sale by the reporting person, which maintains clarity for shareholders reviewing insider activity.